A monoclonal antibody demonstrating specificity for drug-resistance cells

Related Experiment Video

Updated: Aug 12, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

C J O'Hara, G B Price

    Immunology Letters
    |July 1, 1982
    PubMed

    We have described a monoclonal antibody with specificity for permeability-altered drug-resistant cells. This gamma G2b antibody was characterized by antibody-mediated complement-dependent cytotoxicity and by immunofluorescence analysis using a flow cytometer-cell sorter. Further experiments with the flow cytometer showed that vinblastine=resistant cells exposed to that drug had a wider range of fluorescence intensity and had a modal channel 4 times as bright as the same cells cultured in growth medium. We believe that this monoclonal antibody recognizes part of the "P' glycoprotein found on drug-resistant Chinese hamster ovary cells.

    More Related Videos

    Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay07:52

    Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

    Published on: September 10, 2018

    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

    Published on: May 16, 2020

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Hybridoma Technology01:31

    Hybridoma Technology

    Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
    Hybridoma Selection
    Commonly used fusion techniques — electroporation, polyethylene glycol...